A Look At Arcellx (ACLX) Valuation After New US$209.2 Million Shelf Registration Filing

Simply Wall St.01-06

Arcellx (ACLX) has filed a shelf registration to offer up to $209.2 million in common stock, covering 3,208,367 shares tied to an employee stock ownership plan, which is raising fresh questions about ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601707860?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-01-06 14:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601707860","market":"hk","top_or_hot":-1,"title":"A Look At Arcellx (ACLX) Valuation After New US$209.2 Million Shelf Registration Filing","media":"Simply Wall St.","content":"<div>\n<p>Arcellx (ACLX) has filed a shelf registration to offer up to $209.2 million in common stock, covering 3,208,367 shares tied to an employee stock ownership plan, which is raising fresh questions about ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aclx/arcellx/news/a-look-at-arcellx-aclx-valuation-after-new-us2092-million-sh\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Arcellx (ACLX) Valuation After New US$209.2 Million Shelf Registration Filing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Arcellx (ACLX) Valuation After New US$209.2 Million Shelf Registration Filing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-06 14:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aclx/arcellx/news/a-look-at-arcellx-aclx-valuation-after-new-us2092-million-sh><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Arcellx (ACLX) has filed a shelf registration to offer up to $209.2 million in common stock, covering 3,208,367 shares tied to an employee stock ownership plan, which is raising fresh questions about ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aclx/arcellx/news/a-look-at-arcellx-aclx-valuation-after-new-us2092-million-sh\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ACLX","symbol_name":"ARCELLX, INC.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aclx/arcellx/news/a-look-at-arcellx-aclx-valuation-after-new-us2092-million-sh","article_id":"2601707860","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aclx/arcellx/news/a-look-at-arcellx-aclx-valuation-after-new-us2092-million-sh","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2601707860","pubTimestamp":1767680246,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Arcellx (ACLX) has filed a shelf registration to offer up to $209.2 million in common stock, covering 3,208,367 shares tied to an employee stock ownership plan, which is raising fresh questions about future capital needs.\nSee our latest analysis for Arcellx.\nThe shelf registration comes after a roughly 30% decline in the 90 day share price return and an 11% drop over 30 days, even though the 3 year total shareholder return is close to a 2x gain. Some investors may see the capital raising...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"ACLX":"ARCELLX, INC.","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4139":"生物科技"},"translate_title":"Arcellx(ACLX)新提交2.092亿美元搁置注册后的估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACLX":1.5,"DCF":1},"content_text":"Arcellx (ACLX) has filed a shelf registration to offer up to $209.2 million in common stock, covering 3,208,367 shares tied to an employee stock ownership plan, which is raising fresh questions about future capital needs. See our latest analysis for Arcellx. The shelf registration comes after a roughly 30% decline in the 90 day share price return and an 11% drop over 30 days, even though the 3 year total shareholder return is close to a 2x gain. Some investors may see the capital raising flexibility as adding financing risk, while others may focus on longer term value creation potential implied by that multi year total shareholder return. If this kind of capital raising activity has you reassessing your watchlist, it could be a good moment to look at other healthcare stocks that are moving on clinical and funding news of their own. With the share price down over the past year, but a 3-year total return close to 2x and the stock trading below some valuation estimates, you have to ask: is Arcellx undervalued, or is future growth already priced in? AdvertisementPrice to Book of 8.1x: Is it justified? Arcellx is trading on a P/B of 8.1x at a last close of US$61.83, which looks cheap against some peers yet expensive versus the wider US biotech group. P/B compares the company’s market value to its net assets, which matters for a clinical stage biotech where tangible equity and cash resources are key reference points for investors. According to Simply Wall St’s valuation checks, Arcellx is described as good value when you compare its 8.1x P/B to a peer average of 15.9x, which suggests the market is not assigning the same premium as it does to similar names. Against the broader US Biotechs industry though, the same 8.1x P/B is labelled expensive relative to the 2.7x industry average. This is a strong reminder that this is a higher priced stock on a balance sheet basis compared to the sector overall. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-book of 8.1x (ABOUT RIGHT) However, you still have to weigh the recent share price declines and the ongoing net loss of US$217.903 million, which may act as potential pressure points for sentiment and funding expectations. Find out about the key risks to this Arcellx narrative. Another View: Our DCF Model Paints A Very Different Picture If you put the P/B ratio to one side and look at the SWS DCF model, the gap is striking. Arcellx is described as trading about 87.1% below an estimated fair value of US$478.38, which is a very large discount. Is this a mispricing or a reflection of the risks around future cash flows? Look into how the SWS DCF model arrives at its fair value. ACLX Discounted Cash Flow as at Jan 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Arcellx for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 877 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own Arcellx Narrative If you want to weigh the same numbers differently or focus on your own set of assumptions, you can build a personalised view of Arcellx in just a few minutes with Do it your way. A great starting point for your Arcellx research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision. Ready to hunt for more stock ideas? If Arcellx is only one piece of your watchlist, now is the time to cast a wider net and pressure test your next investment moves.  Target potential mispricings by reviewing these 877 undervalued stocks based on cash flows that line up with your view on risk and reward. Spot early tech themes by scanning these 25 AI penny stocks that tie artificial intelligence to real business models. Evaluate opportunities for cash distributions by checking out these 14 dividend stocks with yields > 3% that may suit an income focused portfolio.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601707860","isCrawlerRequest":true}